Question 1

What is the company's focus?

Accepted Answer

The company is a genetic medicines company developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.

Question 2

What is the company's technology platform?

Accepted Answer

The company maintains and licenses its Captisol® technology platform, which has broad applicability in drug development and is used by a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world.

Question 3

What recent achievements has the company made?

Accepted Answer

The company's Zelsuvmi™ product has received U.S. FDA approval as a first-in-class medication for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. Additionally, the company has acquired royalties on Sanofi's Tzield® product.

Question 4

What is the company's investment strategy?

Accepted Answer

The company is a specialist in healthcare investing and manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry. The company invests in the clinical development and commercialization of high-value medicines.

Voyager DB

Contact Research

Chrome Extension

Ligand Pharmaceuticals

Company Overview

Company Name

Address

Website

Phone

Approx. Annual Revenue

Employees

Established

About Ligand Pharmaceuticals

Business Profile

About the website

More Companies in California

Frequently Asked Questions about Ligand Pharmaceuticals

What is the company's focus?

What is the company's technology platform?

What recent achievements has the company made?

What is the company's investment strategy?

Categories

Technologies Used

Social Profiles

Key Decision Makers